Lenalidomide and thalidomide | 合法藥品大搜索

由KCAnderson著作·2005·被引用264次—Firstestablishedasagentswithantiangiogenicproperties,thalidomideandIMiDsinhibittheproductionofinterleukin(IL)-6,whichisagrowthfactorforthe ...

Multiple myeloma is a B-cell malignancy characterized by an excess of monotypic plasma cells in the bone marrow. The molecular mechanisms that are involved in disease progression depend on the interaction between the multiple myeloma cells and the bone microenvironment. Because these mechanisms have been well characterized, it is possible to develop regimens that are more specific to pathways involved in the pathogenesis of multiple myeloma than is typical for conventional chemotherapy in disease management. Thalidomide and immunomodulatory drugs (IMiDs) have now been shown to block several pathways important for disease progression in multiple myeloma. First established as agents with antiangiogenic properties, thalidomide and IMiDs inhibit the production of interleukin (IL)-6, which is a growth factor for the proliferation of myeloma cells. In addition, they activate apoptotic pathways through caspase 8-mediated c...

Lenalidomide 治療多發性骨髓瘤之新選擇 | 合法藥品大搜索

(Velcade®)、免疫調節劑(immunomodulatory drugs, IMiDs) 如thalidomide (Thado®) 及 lenalidomide (Revlimid®) 的問世，提升了對多發性骨髓瘤之治療反應率及 ... Read More

Lenalidomide and thalidomide | 合法藥品大搜索

由 KC Anderson 著作 · 2005 · 被引用 264 次 — First established as agents with antiangiogenic properties, thalidomide and IMiDs inhibit the production of interleukin (IL)-6, which is a growth factor for the ... Read More

Lenalidomide versus thalidomide based regimens as first | 合法藥品大搜索

由 Y Zou 著作 · 2013 · 被引用 18 次 — In conclusion, lenalidomide seems to be a more potent and less toxic agent than thalidomide in the treatment of patients with multiple myeloma. Further, a direct ... Read More

Thalidomide and lenalidomide | 合法藥品大搜索

由 S Vallet 著作 · 2008 · 被引用 120 次 — Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of ... Read More

Comparative effectiveness and safety of ... | 合法藥品大搜索

由 J Luo 著作 · 2017 · 被引用 22 次 — Our results agree with the findings of recently published trials suggesting that thalidomide and lenalidomide are equivalent with respect to survival outcomes but ... Read More

Bortezomib | 合法藥品大搜索

由 M Mian 著作 · 2016 · 被引用 13 次 — Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? Anticancer Res. 2016 Mar;36(3):1059-65. Read More

Lenalidomide (Revlimid) | 合法藥品大搜索

由 MP Cruz 著作 · 2016 · 被引用 9 次 — Lenalidomide (Revlimid, Celgene) is a thalidomide derivative introduced in 2004 as an immunomodulatory agent for the treatment of various cancers such as ... Read More

多發性骨髓瘤的用藥治療作者：臺大醫院藥劑部藥師林欣儀專題 ... | 合法藥品大搜索

Lenalidomide不如thalidomide有周邊神經炎的問題，卻較容易發生骨髓抑制導致貧血、血小板低下與白血球低下。其他常見的副作用包括頭昏、頭痛、失眠、腹瀉、 ... Read More

Comparative effectiveness and safety of thalidomide and ... | 合法藥品大搜索

由 J Luo 著作 · 2017 · 被引用 22 次 — For patients with multiple myeloma, we found that initiating treatment with lenalidomide in the context of routine care had no significant advantage over thalidomide ... Read More

Lenalidomide | 合法藥品大搜索

Multiple myeloma[edit]. Lenalidomide is used to treat multiple myeloma. ... It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, ... Read More

相關資訊整理